UroGen Pharma (URGN) EBIT Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly EBIT Margin came in at 39.76% in Q1 2026, up 14249.0% YoY from N/an in Q1 2025, and up 21.29% on a QoQ basis from 50.52% in Q4 2025.
UroGen Pharma (URGN) EBIT Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of EBIT Margin data on file, last reported at 39.76% in Q1 2026.
- Quarterly EBIT Margin rose 14249.0% year-over-year to 39.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.02% (up 4049.0% YoY) and the FY2025 annual result came in at 113.73%, down 667.0% from the prior year.
- EBIT Margin rose to 39.76% in Q1 2026, from 50.52% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 39.76% in Q1 2026 to a low of 182.26% in Q1 2025.
- A 5-year average of 106.34% and a median of 112.36% in 2022 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 18701 bps — and 2025, when it slumped 5290 bps.
- Tracing URGN's EBIT Margin over 5 years: stood at 112.1% in 2022, then jumped by 45 bps to 62.09% in 2023, then plunged by 81 bps to 112.59% in 2024, then soared by 55 bps to 50.52% in 2025, then rose by 21 bps to 39.76% in 2026.
- The last three EBIT Margin figures came in at 39.76% (Q1 2026), 50.52% (Q4 2025), and 99.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 0.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.15% |
| Mar 31, 2026 | -39.76% |
| Dec 31, 2025 | -50.52% |
| Sep 30, 2025 | -99.65% |
| Jun 30, 2025 | -171.17% |
| Mar 31, 2025 | -182.26% |
| Dec 31, 2024 | -112.59% |
| Sep 30, 2024 | -69.61% |
| Jun 30, 2024 | -118.27% |
| Mar 31, 2024 | -137.05% |
| Dec 31, 2023 | -62.09% |
| Sep 30, 2023 | -64.74% |
| Jun 30, 2023 | -72.77% |
| Mar 31, 2023 | -128.23% |
| Dec 31, 2022 | -112.10% |
| Sep 30, 2022 | -112.36% |
| Jun 30, 2022 | -112.71% |
| Mar 31, 2022 | -161.88% |
| Dec 31, 2021 | -123.13% |
| Sep 30, 2021 | -206.50% |